Abstract: Use of a recombinant transforming growth factor beta induced (TGFBI) protein in lattice corneal dystrophy (LCD) is provided, belonging to the technical field of biomedicine. Use of a recombinant TGFBI protein and a recombinant TGFBI protein-expressing reagent in preparation of a medicament for treating LCD are provided. It is confirmed that dropping eye drops of the recombinant TGFBI protein can promote the repair of corneal epithelial damages in an LCD mouse model; corneal intrastromal injection of the recombinant TGFBI protein can promote the repair of corneal epithelial damages in the LCD mouse model; and limbal intrastromal injection of an adeno-associated virus (AAV) vector carrying a Tgfbi gene can promote the repair of epithelial damages in a TGFBI point mutation-carrying mouse. Therefore, the recombinant TGFBI protein-related reagents exhibit a potential to treat the LCD.

Abstract: In view of the problem that the current prevention and treatment manners for corneal neovascularization (CNV) may cause complications, the present disclosure provides an application of CB-839 in preparation of a drug for inhibiting CNV. The CB-839-loaded drug of the present disclosure can significantly inhibit CNV in mice and reduce the infiltration of inflammatory cells without obvious side effects, which makes up for the shortcoming of the prior art.

Abstract: In view of the problem that the current prevention and treatment manners for corneal neovascularization (CNV) may cause complications, the present disclosure provides an application of CB-839 in preparation of a drug for inhibiting CNV. The CB-839-loaded drug of the present disclosure can significantly inhibit CNV in mice and reduce the infiltration of inflammatory cells without obvious side effects, which makes up for the shortcoming of the prior art.

Abstract: Disclosed are probes, primers, a microarray, a kit and applications for rapid detection of clinical microorganism in ophthalmology, belonging to that technical field of clinical microorganism detection. The probes of that disclosure comprise probes for respectively detect Staphylococcus epidermidis, Staphylococcus aureus, Staphylococcus haemolyticus, Pseudomonas aeruginosa, Staphylococcus hominis, Serratia marcescens, Escherichia coli, Bacillus subtilis and Enterobacter cloacae. The disclosure also discloses primers for amplifying the target bacteria, which comprises primers which can amplify gene sequence fragments with intra-species homology of more than 95 percent (%) and inter-species homology of less than 75%. The disclosure also provides a method for synthesizing the hybridization probe on the microarray, a method for hybridization reaction and a method for scanning detection.

Abstract: Disclosed are probes, primers, a microarray, a kit and applications for rapid detection of clinical microorganism in ophthalmology, belonging to that technical field of clinical microorganism detection. The probes of that disclosure comprise probes for respectively detect Staphylococcus epidermidis, Staphylococcus aureus, Staphylococcus haemolyticus, Pseudomonas aeruginosa, Staphylococcus hominis, Serratia marcescens, Escherichia coli, Bacillus subtilis and Enterobacter cloacae. The disclosure also discloses primers for amplifying the target bacteria, which comprises primers which can amplify gene sequence fragments with intra-species homology of more than 95 percent (%) and inter-species homology of less than 75%. The disclosure also provides a method for synthesizing the hybridization probe on the microarray, a method for hybridization reaction and a method for scanning detection.